The quantity of data about medicines, diseases, and biology is growing. So too, are the number of companies that employ artificial intelligence in drug discovery. Most of the low-hanging fruit in drug research has already been picked, and the industry is clamoring to make sense of the new data, according to Jeffrey Lu, CEO and co-founder of Engine Biosciences. “There’s only one way to do that—use machines to process the complexity,” Lu said.

Source: Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

Leave a Reply

Your email address will not be published.